読み込み中
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
前日終値
$0.4671
−$0.002 · -0.43%
日中の時刻はETです。市場データは遅延する場合があります。
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
日中レンジ
現在 $0.4671
52週レンジ
現在 $0.4671
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
50
適正価値
センチメント
56
まちまち
リスク
70
高リスク
モメンタム
35
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
日中レンジ
現在 $0.4671
52週レンジ
現在 $0.4671
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 106.02万 USD | 213万 USD | 690.8万 USD | 157.93万 USD | 8.2万 USD |
| 販売・一般管理 | 217.48万 USD | 208.9万 USD | 252万 USD | 208.59万 USD | 102.1万 USD |
| 営業費用 | 323.49万 USD | 421.9万 USD | 942.8万 USD | 366.52万 USD | 110.31万 USD |
| 受取利息 | 12.2万 USD | 5.57万 USD | 1868 USD | — | 805.11 USD |
| 支払利息 | — | — | — | 73.17万 USD | 80.51万 USD |
| 減価償却費と償却費 | — | 421.92万 USD | 942.83万 USD | — | — |
| 営業利益 | −323.49万 USD | −421.9万 USD | −942.8万 USD | −366.52万 USD | −110.31万 USD |
| 純利益 | −310.9万 USD | −411.2万 USD | −894.9万 USD | −148.46万 USD | −161.07万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
